Identification

Name
Empagliflozin
Accession Number
DB09038
Type
Small Molecule
Groups
Approved
Description

Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, therefore resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia and also assists weight loss and blood pressure reduction.

Structure
Thumb
Synonyms
  • (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol
  • 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene
External IDs
BI 10773 / BI-10773 / BI10773
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
JardianceTablet10 mgOralBoehringer Ingelheim (Canada) Ltd Ltee2015-08-11Not applicableCanada
JardianceTablet, film coated25 mg/1OralBoehringer Ingelheim2014-08-01Not applicableUs
JardianceTablet25 mgOralBoehringer Ingelheim (Canada) Ltd Ltee2015-08-11Not applicableCanada
JardianceTablet, film coated10 mg/1OralCardinal Health2014-08-01Not applicableUs
JardianceTablet, film coated10 mg/1OralBoehringer Ingelheim2014-08-01Not applicableUs00597 0152 90 nlmimage10 8d40c686
JardianceTablet, film coated25 mg/1OralCardinal Health2014-08-01Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
GlyxambiEmpagliflozin (25 mg) + Linagliptin (5 mg)TabletOralBoehringer Ingelheim (Canada) Ltd Ltee2016-12-21Not applicableCanada
GlyxambiEmpagliflozin (25 mg/1) + Linagliptin (5 mg/1)Tablet, film coatedOralBoehringer Ingelheim2015-01-30Not applicableUs
GlyxambiEmpagliflozin (10 mg) + Linagliptin (5 mg)TabletOralBoehringer Ingelheim (Canada) Ltd Ltee2016-12-21Not applicableCanada
GlyxambiEmpagliflozin (10 mg/1) + Linagliptin (5 mg/1)Tablet, film coatedOralBoehringer Ingelheim2015-01-30Not applicableUs
SynjardyEmpagliflozin (5 mg) + Metformin (500 mg)TabletOralBoehringer Ingelheim (Canada) Ltd Ltee2016-08-03Not applicableCanada
SynjardyEmpagliflozin (5 mg/1) + Metformin (1000 mg/1)TabletOralBoehringer Ingelheim2015-08-26Not applicableUs
SynjardyEmpagliflozin (12.5 mg) + Metformin (500 mg)TabletOralBoehringer Ingelheim (Canada) Ltd Ltee2016-08-03Not applicableCanada
SynjardyEmpagliflozin (5 mg/1) + Metformin (500 mg/1)TabletOralBoehringer Ingelheim2015-08-26Not applicableUs
SynjardyEmpagliflozin (5 mg) + Metformin (850 mg)TabletOralBoehringer Ingelheim (Canada) Ltd Ltee2016-08-03Not applicableCanada
SynjardyEmpagliflozin (12.5 mg/1) + Metformin (500 mg/1)TabletOralBoehringer Ingelheim2015-08-26Not applicableUs
Categories
UNII
HDC1R2M35U
CAS number
864070-44-0
Weight
Average: 450.91
Monoisotopic: 450.1445309
Chemical Formula
C23H27ClO7
InChI Key
OBWASQILIWPZMG-QZMOQZSNSA-N
InChI
InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1
IUPAC Name
(2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
SMILES
[H][[email protected]@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[[email protected]]2([H])O[[email protected]]([H])(CO)[[email protected]@]([H])(O)[[email protected]]([H])(O)[[email protected]@]2([H])O)C=C1

Pharmacology

Indication

Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes.

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia, assists weight loss, and reduces blood pressure.

TargetActionsOrganism
USodium/glucose cotransporter 2
antagonist
inhibitor
Human
Absorption

Following oral administration, peak plasma concentrations were reached at 1.5 hours post-dose and then declined in a biphasic manner with a rapid distribution phase and a relatively slow terminal phase. Administration following a high-fat and high-calorie meal results in a slightly lower exposure with AUC decreasing by approximately 16% and Cmax decreasing by approximately 37% compared to fasted condition.

Volume of distribution

73.8 L

Protein binding

Plasma protein binding was found to be 86.2%

Metabolism

In vitro studies suggest that empaglifozin is primarily metabolized by glucuronidation by 5'-diphospho-glucuronosyltransferases UG2B7, UGT1A3, UGT1A8, and UGT1A9. The most abundant metabolites are three glucuronide metabolites: 2-O-, 3-O-, and 6-O-glucuronide. Empagliflozin does not inhibit, inactivate, or induce CYP450 isoforms. It is a substrate for p-glycoprotein (p-gp), however in vitro studies suggest that it is unlikely to cause interactions with drugs that are p-gp substrates.

Route of elimination

After oral administration, empaglifozin was 41.2% eliminated in feces and 54.4% eliminated in urine.

Half life

Terminal elimination half life was found to be 12.4 h based on population pharmacokinetic analysis.

Clearance

Apparent oral clearance was found to be 10.6 L/h based on population pharmacokinetic analysis.

Toxicity

The most commonly reported adverse effects for empaglifozin were urinary tract infections, female genital mycotic infections, and dyslipidemia. Because empagliflozin causes osmotic diuresis adverse reactions related to volume depletion were also reported (decreased systolic blood pressure, dehydration, hypotension, orthostatic hypotension, hypovolemia, and syncope). Impaired renal function and hypoglycemia were also reported.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Empagliflozin.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Empagliflozin.Approved
AcetohexamideEmpagliflozin may increase the hypoglycemic activities of Acetohexamide.Withdrawn
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Empagliflozin.Approved, Vet Approved
AlaproclateAlaproclate may increase the hypoglycemic activities of Empagliflozin.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Empagliflozin.Approved
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Empagliflozin.Approved, Investigational
AloxiprinAloxiprin may increase the hypoglycemic activities of Empagliflozin.Experimental
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Empagliflozin.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Empagliflozin.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Empagliflozin.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Empagliflozin.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Empagliflozin.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Empagliflozin.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Empagliflozin.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Empagliflozin.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Empagliflozin.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Empagliflozin.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Empagliflozin.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Empagliflozin.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Empagliflozin.Approved, Investigational
ArticaineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Asenapine.Approved
AtazanavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Empagliflozin.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Empagliflozin.Approved
BalsalazideBalsalazide may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Empagliflozin.Experimental
BarbitalBarbital may increase the hypotensive activities of Empagliflozin.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Empagliflozin.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Empagliflozin.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Empagliflozin.Approved
BenmoxinBenmoxin may increase the hypoglycemic activities of Empagliflozin.Withdrawn
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Empagliflozin.Approved, Withdrawn
BetamethasoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Empagliflozin.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Empagliflozin.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Empagliflozin.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Empagliflozin.Approved
BrexpiprazoleThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Empagliflozin.Approved
BrofaromineBrofaromine may increase the hypoglycemic activities of Empagliflozin.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Empagliflozin.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Empagliflozin.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Empagliflozin.Approved, Investigational
BuserelinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Buserelin.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Empagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Empagliflozin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Empagliflozin.Approved
Carbaspirin calciumCarbaspirin calcium may increase the hypoglycemic activities of Empagliflozin.Experimental
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Empagliflozin.Approved
CarbutamideEmpagliflozin may increase the hypoglycemic activities of Carbutamide.Experimental
CaroxazoneCaroxazone may increase the hypoglycemic activities of Empagliflozin.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Empagliflozin.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Empagliflozin.Approved, Investigational
CeritinibThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ceritinib.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Empagliflozin.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Empagliflozin.Approved, Vet Approved
ChlorpropamideEmpagliflozin may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Empagliflozin.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Empagliflozin.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Empagliflozin.Approved
CinoxacinCinoxacin may increase the hypoglycemic activities of Empagliflozin.Approved, Withdrawn
CitalopramCitalopram may increase the hypoglycemic activities of Empagliflozin.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Empagliflozin.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Empagliflozin.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Empagliflozin.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Empagliflozin.Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Empagliflozin.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Empagliflozin.Approved, Investigational
CorticotropinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Cortisone acetate.Approved
CyclopenthiazideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Cyclopenthiazide.Experimental
Cyproterone acetateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
DabrafenibThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dabrafenib.Approved
DanazolThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Danazol.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Empagliflozin.Approved
DapoxetineDapoxetine may increase the hypoglycemic activities of Empagliflozin.Investigational
DarunavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Darunavir.Approved
dersalazinedersalazine may increase the hypoglycemic activities of Empagliflozin.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Empagliflozin.Approved
DesogestrelThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Desogestrel.Approved
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Empagliflozin.Approved
DexamethasoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Empagliflozin.Approved, Vet Approved
DiazoxideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Diazoxide.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Empagliflozin.Approved
DienogestThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dienogest.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Empagliflozin.Approved
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Empagliflozin.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Empagliflozin.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Empagliflozin.Approved
DisopyramideEmpagliflozin may increase the hypoglycemic activities of Disopyramide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Empagliflozin.Approved
DrospirenoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Drospirenone.Approved
DuloxetineEmpagliflozin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Empagliflozin.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Empagliflozin.Approved
EnoxacinEnoxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpinephrineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Empagliflozin.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Empagliflozin.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Empagliflozin.Approved
EscitalopramEscitalopram may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Empagliflozin.Approved
EstradiolThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estradiol.Approved, Investigational, Vet Approved
Estrone sulfateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Empagliflozin.Approved
Ethinyl EstradiolThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethinyl Estradiol.Approved
Ethynodiol diacetateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethynodiol diacetate.Approved
EtonogestrelThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoperidoneEtoperidone may increase the hypoglycemic activities of Empagliflozin.Approved
EverolimusThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Everolimus.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Empagliflozin.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Empagliflozin.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Empagliflozin.Approved
FleroxacinFleroxacin may increase the hypoglycemic activities of Empagliflozin.Approved
FludrocortisoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Fludrocortisone.Approved
FlumequineFlumequine may increase the hypoglycemic activities of Empagliflozin.Withdrawn
FluoxetineFluoxetine may increase the hypoglycemic activities of Empagliflozin.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Empagliflozin.Approved, Illicit
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational
FosamprenavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Fosamprenavir.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Empagliflozin.Approved
FurazolidoneFurazolidone may increase the hypoglycemic activities of Empagliflozin.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Empagliflozin.Approved, Vet Approved
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Empagliflozin.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational
GemifloxacinGemifloxacin may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational
GlibornurideEmpagliflozin may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideEmpagliflozin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideEmpagliflozin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideEmpagliflozin may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneEmpagliflozin may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideEmpagliflozin may increase the hypoglycemic activities of Glisoxepide.Approved
GLPG-0492GLPG-0492 may increase the hypoglycemic activities of Empagliflozin.Investigational
GlyburideEmpagliflozin may increase the hypoglycemic activities of Glyburide.Approved
GoserelinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Goserelin.Approved
GrepafloxacinGrepafloxacin may increase the hypoglycemic activities of Empagliflozin.Withdrawn
GuacetisalGuacetisal may increase the hypoglycemic activities of Empagliflozin.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Empagliflozin.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Empagliflozin.Approved, Vet Approved
HarmalineHarmaline may increase the hypoglycemic activities of Empagliflozin.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the hypoglycemic activities of Empagliflozin.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Empagliflozin.Approved
HistrelinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Histrelin.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Empagliflozin.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Empagliflozin.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Empagliflozin.Approved, Vet Approved
HydrocortisoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Empagliflozin.Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
IloperidoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Empagliflozin.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Empagliflozin.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Empagliflozin.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Empagliflozin.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Empagliflozin.Approved
IndinavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Indinavir.Approved
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Empagliflozin.Withdrawn
Insulin AspartEmpagliflozin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirEmpagliflozin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineEmpagliflozin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineEmpagliflozin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanEmpagliflozin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproEmpagliflozin may increase the hypoglycemic activities of Insulin Lispro.Approved
Insulin PorkEmpagliflozin may increase the hypoglycemic activities of Insulin Pork.Approved
IproclozideIproclozide may increase the hypoglycemic activities of Empagliflozin.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Empagliflozin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Empagliflozin.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Empagliflozin.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Empagliflozin.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Empagliflozin.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Empagliflozin.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Empagliflozin.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Empagliflozin.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Empagliflozin.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Empagliflozin.Approved
LanreotideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lanreotide.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Empagliflozin.Approved, Investigational
LeuprolideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Leuprolide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Empagliflozin.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Empagliflozin.Approved
LevodopaEmpagliflozin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinLevofloxacin may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Empagliflozin.Approved
LevonorgestrelThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Empagliflozin.Approved, Investigational
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Empagliflozin.Approved, Nutraceutical
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Empagliflozin.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Empagliflozin.Approved, Investigational
LopinavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lopinavir.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Empagliflozin.Approved
LurasidoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lurasidone.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Empagliflozin.Approved, Investigational
MebanazineMebanazine may increase the hypoglycemic activities of Empagliflozin.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Empagliflozin.Approved
MecaserminEmpagliflozin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Medroxyprogesterone acetateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MesalazineMesalazine may increase the hypoglycemic activities of Empagliflozin.Approved
MesteroloneMesterolone may increase the hypoglycemic activities of Empagliflozin.Experimental
MestranolThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Mestranol.Approved
MetahexamideEmpagliflozin may increase the hypoglycemic activities of Metahexamide.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Empagliflozin.Approved
MethohexitalMethohexital may increase the hypotensive activities of Empagliflozin.Approved
MethotrimeprazineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Methotrimeprazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Empagliflozin.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Empagliflozin.Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Empagliflozin.Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Empagliflozin.Approved
MethylprednisoloneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Empagliflozin.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Empagliflozin.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Empagliflozin.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Empagliflozin.Approved, Investigational
MifepristoneEmpagliflozin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the hypoglycemic activities of Empagliflozin.Approved
MinaprineMinaprine may increase the hypoglycemic activities of Empagliflozin.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Empagliflozin.Approved
MoclobemideMoclobemide may increase the hypoglycemic activities of Empagliflozin.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Empagliflozin.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Empagliflozin.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Empagliflozin.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Empagliflozin.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Empagliflozin.Approved
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Empagliflozin.Approved
NandroloneNandrolone may increase the hypoglycemic activities of Empagliflozin.Experimental
NateglinideEmpagliflozin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Empagliflozin.Approved, Investigational
NefazodoneNefazodone may increase the hypoglycemic activities of Empagliflozin.Approved, Withdrawn
NelfinavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Empagliflozin.Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Empagliflozin.Approved, Investigational
NiacinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NialamideNialamide may increase the hypoglycemic activities of Empagliflozin.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Empagliflozin.Approved
NicorandilNicorandil may increase the hypotensive activities of Empagliflozin.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Empagliflozin.Approved
NilotinibThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Empagliflozin.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Empagliflozin.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Empagliflozin.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Empagliflozin.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Empagliflozin.Approved
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Empagliflozin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Empagliflozin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Empagliflozin.Approved
NorethisteroneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
NorgestimateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Norgestimate.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Empagliflozin.Approved
OctamoxinOctamoxin may increase the hypoglycemic activities of Empagliflozin.Withdrawn
OctreotideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Octreotide.Approved, Investigational
OlanzapineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Olanzapine.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Empagliflozin.Approved, Investigational
OlsalazineOlsalazine may increase the hypoglycemic activities of Empagliflozin.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational
Oxolinic acidOxolinic acid may increase the hypoglycemic activities of Empagliflozin.Experimental
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Empagliflozin.Approved
OxymetholoneOxymetholone may increase the hypoglycemic activities of Empagliflozin.Approved, Illicit
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Empagliflozin.Approved, Vet Approved
PaliperidoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Paliperidone.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Empagliflozin.Approved
PargylinePargyline may increase the hypoglycemic activities of Empagliflozin.Approved
ParoxetineParoxetine may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational
PasireotideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pasireotide.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Empagliflozin.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Empagliflozin.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Empagliflozin.Approved, Investigational
PentamidineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pentamidine.Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Empagliflozin.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Empagliflozin.Approved
PhenelzinePhenelzine may increase the hypoglycemic activities of Empagliflozin.Approved
PheniprazinePheniprazine may increase the hypoglycemic activities of Empagliflozin.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Empagliflozin.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Empagliflozin.Approved
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Empagliflozin.Withdrawn
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Empagliflozin.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Empagliflozin.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Empagliflozin.Approved
Pipemidic acidPipemidic acid may increase the hypoglycemic activities of Empagliflozin.Experimental
PiperazineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pipotiazine.Approved
PirlindolePirlindole may increase the hypoglycemic activities of Empagliflozin.Approved
Piromidic acidPiromidic acid may increase the hypoglycemic activities of Empagliflozin.Experimental
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Empagliflozin.Withdrawn
PolythiazideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Empagliflozin.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Empagliflozin.Approved
PrednisoloneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Prednisone.Approved, Vet Approved
PrimidonePrimidone may increase the hypotensive activities of Empagliflozin.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Progesterone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Empagliflozin.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Empagliflozin.Approved, Investigational
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Empagliflozin.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Empagliflozin.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Empagliflozin.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Quinethazone.Approved
QuinineEmpagliflozin may increase the hypoglycemic activities of Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Empagliflozin.Approved
RasagilineRasagiline may increase the hypoglycemic activities of Empagliflozin.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Empagliflozin.Approved
RepaglinideEmpagliflozin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Empagliflozin.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Empagliflozin.Approved
RisperidoneEmpagliflozin may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ritonavir.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Empagliflozin.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Empagliflozin.Approved
RosoxacinRosoxacin may increase the hypoglycemic activities of Empagliflozin.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Empagliflozin.Approved
RufloxacinRufloxacin may increase the hypoglycemic activities of Empagliflozin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Empagliflozin.Approved
SafrazineSafrazine may increase the hypoglycemic activities of Empagliflozin.Withdrawn
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Empagliflozin.Approved, Vet Approved
SaquinavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Saquinavir.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Empagliflozin.Approved, Vet Approved
SelegilineSelegiline may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational, Vet Approved
SertralineSertraline may increase the hypoglycemic activities of Empagliflozin.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Empagliflozin.Approved, Vet Approved
SirolimusThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Sirolimus.Approved, Investigational
SitafloxacinSitafloxacin may increase the hypoglycemic activities of Empagliflozin.Experimental
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Empagliflozin.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Empagliflozin.Approved
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Empagliflozin.Approved
StanozololStanozolol may increase the hypoglycemic activities of Empagliflozin.Approved, Vet Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Empagliflozin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Empagliflozin.Approved, Investigational
SulfadiazineEmpagliflozin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleEmpagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleEmpagliflozin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SunitinibEmpagliflozin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TacrolimusThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tacrolimus.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Empagliflozin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Empagliflozin.Approved, Investigational
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Empagliflozin.Withdrawn
TemsirolimusThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Temsirolimus.Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Empagliflozin.Approved
TestosteroneTestosterone may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Empagliflozin.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Empagliflozin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Empagliflozin.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Empagliflozin.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Empagliflozin.Approved
TipranavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Empagliflozin.Approved
TolazamideEmpagliflozin may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Empagliflozin.Approved, Vet Approved
TolbutamideEmpagliflozin may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Empagliflozin.Approved, Withdrawn
ToloxatoneToloxatone may increase the hypoglycemic activities of Empagliflozin.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Empagliflozin.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Empagliflozin.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Empagliflozin.Experimental
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Empagliflozin.Approved
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Empagliflozin.Approved, Investigational, Nutraceutical
TriamcinoloneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Empagliflozin.Approved
TrichlormethiazideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TriptorelinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Triptorelin.Approved, Vet Approved
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Empagliflozin.Approved, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Empagliflozin.Approved, Investigational
VenlafaxineVenlafaxine may increase the hypoglycemic activities of Empagliflozin.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Empagliflozin.Approved
VorinostatThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Vorinostat.Approved, Investigational
ZimelidineZimelidine may increase the hypoglycemic activities of Empagliflozin.Withdrawn
ZiprasidoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ziprasidone.Approved
Food Interactions
Not Available

References

Synthesis Reference

Wang XJ, Zhang L, Byrne D, Nummy L, Weber D, Krishnamurthy D, Yee N, Senanayake CH: Efficient synthesis of Empagliflozin, an inhibitor of SGLT-2, utilizing an AlCl3-promoted silane reduction of a beta-glycopyranoside. Org Lett. 2014 Aug 15;16(16):4090-3. doi: 10.1021/ol501755h. Epub 2014 Jul 25. Pubmed

General References
  1. Scheen AJ: Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Clin Pharmacokinet. 2015 Jul;54(7):691-708. doi: 10.1007/s40262-015-0264-4. [PubMed:25805666 ]
  2. Gangadharan Komala M, Mather A: Empagliflozin for the treatment of Type 2 diabetes. Expert Rev Clin Pharmacol. 2014 May;7(3):271-9. doi: 10.1586/17512433.2014.908703. Epub 2014 Apr 9. [PubMed:24716752 ]
  3. Lamos EM, Younk LM, Davis SN: Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs. 2014 Jun;23(6):875-82. doi: 10.1517/13543784.2014.909407. Epub 2014 Apr 19. [PubMed:24746173 ]
  4. Liakos A, Karagiannis T, Athanasiadou E, Sarigianni M, Mainou M, Papatheodorou K, Bekiari E, Tsapas A: Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014 Oct;16(10):984-93. doi: 10.1111/dom.12307. Epub 2014 May 28. [PubMed:24766495 ]
  5. Haring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle HJ: Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014 Jun;37(6):1650-9. doi: 10.2337/dc13-2105. Epub 2014 Apr 10. [PubMed:24722494 ]
  6. Neumiller JJ: Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context. 2014 Jun 11;3:212262. doi: 10.7573/dic.212262. eCollection 2014. [PubMed:24991224 ]
  7. Bogdanffy MS, Stachlewitz RF, van Tongeren S, Knight B, Sharp DE, Ku W, Hart SE, Blanchard K: Nonclinical safety of the sodium-glucose cotransporter 2 inhibitor empagliflozin. Int J Toxicol. 2014 Nov-Dec;33(6):436-49. doi: 10.1177/1091581814551648. Epub 2014 Sep 26. [PubMed:25260362 ]
  8. Authors unspecified: Empagliflozin (Jardiance) for diabetes. Med Lett Drugs Ther. 2014 Oct 13;56(1453):99-100. [PubMed:25296258 ]
  9. Jahagirdar V, Barnett AH: Empagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2014 Nov;15(16):2429-41. doi: 10.1517/14656566.2014.966078. [PubMed:25301180 ]
External Links
KEGG Drug
D10459
PubChem Compound
11949646
PubChem Substance
310264986
ChemSpider
10123957
BindingDB
150162
ChEBI
82720
ChEMBL
CHEMBL2107830
PharmGKB
PA166163327
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Empagliflozin
ATC Codes
A10BX12 — EmpagliflozinA10BD19 — Linagliptin and empagliflozinA10BD20 — Metformin and empagliflozin
AHFS Codes
  • 68:20.18
PDB Entries
Not Available
FDA label
Download (604 KB)
MSDS
Download (99 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentHealthy Volunteers1
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceDiabetes Mellitus (DM)1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentHealthy Volunteers23
1CompletedTreatmentHealthy Volunteers / Hepatic Insufficiency1
1CompletedTreatmentType 2 Diabetes Mellitus7
1Not Yet RecruitingTreatmentType 2 Diabetes Mellitus1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 13
2CompletedTreatmentHealthy Volunteers / Type 2 Diabetes Mellitus1
2CompletedTreatmentType 2 Diabetes Mellitus8
2Enrolling by InvitationTreatmentHeart Failure, Unspecified / Type 2 Diabetes Mellitus1
2Not Yet RecruitingTreatmentChronic Heart Failure (CHF)1
2Not Yet RecruitingTreatmentHeart Failure Acute / Heart Failure; With Decompensation / Heart Failure,Congestive1
2RecruitingBasic ScienceRenal Dysfunction1
2RecruitingTreatmentChronic Kidney Disease stage3 / Chronic Kidney Disease stage4 / Diabetic Kidney Disease / Type 2 Diabetes Mellitus1
2RecruitingTreatmentDiabetes Type 2 With Heart Failure1
2RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
2RecruitingTreatmentHeart Failure With Reduced Ejection Fraction (HFrEF)1
2RecruitingTreatmentPosttransplant Diabetes Mellitus1
2RecruitingTreatmentType 2 Diabetes Mellitus2
2, 3Enrolling by InvitationTreatmentSIADH1
2, 3RecruitingHealth Services ResearchPolycystic Ovaries Syndrome1
2, 3RecruitingTreatmentHyponatremias / SIAD - Syndrome of Inappropriate Antidiuresis1
3Active Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 12
3Active Not RecruitingTreatmentDiabetes / Type 2 Diabetes Mellitus1
3Active Not RecruitingTreatmentType 2 Diabetes Mellitus1
3CompletedTreatmentBMI >30 kg/m2 / Type 2 Diabetes Mellitus1
3CompletedTreatmentHypertensive / Type 2 Diabetes Mellitus1
3CompletedTreatmentImpaired Renal Function / Type 2 Diabetes Mellitus1
3CompletedTreatmentType 2 Diabetes Mellitus13
3Not Yet RecruitingPreventionDiabetes, Gestational1
3RecruitingTreatmentAcute Myocardial Infarction (AMI)1
3RecruitingTreatmentDiabetic Kidney Disease / Type 2 Diabetes Mellitus1
3RecruitingTreatmentHeart Failure, Unspecified2
3RecruitingTreatmentType 2 Diabetes Mellitus2
3RecruitingTreatmentType2 Diabetes Mellitus1
3Unknown StatusTreatmentType 2 Diabetes Mellitus1
3WithdrawnTreatmentType 2 Diabetes Mellitus1
4CompletedBasic ScienceType 2 Diabetes Mellitus1
4CompletedTreatmentType 2 Diabetes Mellitus1
4Not Yet RecruitingPreventionHypertensive / Type 2 Diabetes Mellitus1
4Not Yet RecruitingTreatmentAdvanced Glycation End Products / Diabetes / SGLT-2 Inhibitors1
4Not Yet RecruitingTreatmentCoronary Heart Disease (CHD) / Diabetes Mellitus (DM)1
4Not Yet RecruitingTreatmentHeart Failure, Unspecified1
4Not Yet RecruitingTreatmentHeart Failure, Unspecified / Type 2 Diabetes Mellitus1
4Not Yet RecruitingTreatmentType 2 Diabetes Mellitus3
4RecruitingDiagnosticCardiovascular Disease (CVD) / Diabetes1
4RecruitingPreventionObesity, Visceral1
4RecruitingTreatmentDiabetes Mellitus (DM) / Impaired Renal Function / Safety Issues1
4RecruitingTreatmentDiastolic Dysfunction / Type 2 Diabetes Mellitus1
4RecruitingTreatmentNAFLD / Type2 Diabetes1
4RecruitingTreatmentNocturnal Hypertension / Type 2 Diabetes Mellitus1
4RecruitingTreatmentNon-Alcoholic Fatty Liver Disease (NAFLD) / Type 2 Diabetes Mellitus1
4RecruitingTreatmentType 2 Diabetes Mellitus2
4RecruitingTreatmentType II Diabetes in Subjects BMI 27 to 32 / Type II Diabetes in the Not so Obese1
Not AvailableActive Not RecruitingNot AvailableType 2 Diabetes Mellitus1
Not AvailableActive Not RecruitingBasic ScienceType 2 Diabetes Mellitus1
Not AvailableActive Not RecruitingTreatmentNon Alcoholic Fatty Liver Diseases (NAFLD)1
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus1
Not AvailableNot Yet RecruitingTreatmentType 2 Diabetes Mellitus1
Not AvailableRecruitingNot AvailableType 2 Diabetes Mellitus2
Not AvailableRecruitingDiagnosticLate Dumping Syndrome / Post-gastrointestinal bypass surgery / Postprandial Hypoglycemia1
Not AvailableRecruitingTreatmentType2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral
TabletOral10 mg
TabletOral25 mg
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral25 mg/1
TabletOral
Tablet, extended releaseOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
USUS7579449 No2005-03-152025-03-15Us
USUS7713938 No2006-04-192026-04-19Us
USWO 201416191 No2014-04-032034-04-03Us
US7407955 No2003-08-122023-08-12Us
US6488962 No2000-06-202020-06-20Us
US6303661 No1997-04-242017-04-24Us
US6890898 No1999-02-022019-02-02Us
US7078381 No1999-02-022019-02-02Us
US7459428 No1999-02-022019-02-02Us
US8119648 No2003-08-122023-08-12Us
US8178541 No2003-08-122023-08-12Us
US8846695 No2010-06-042030-06-04Us
US9173859 No2007-05-042027-05-04Us
US8673927 No2007-05-042027-05-04Us
US8883805 No2005-11-262025-11-26Us
US8551957 No2009-10-192029-10-19Us
US7713938 No2007-04-152027-04-15Us
US7579449 No2005-11-052025-11-05Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.111 mg/mLALOGPS
logP1.79ALOGPS
logP1.66ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)12.57ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area108.61 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity113.79 m3·mol-1ChemAxon
Polarizability45.24 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of chemical entities known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose.
Kingdom
Chemical entities
Super Class
Organic compounds
Class
Organic oxygen compounds
Sub Class
Organooxygen compounds
Direct Parent
Phenolic glycosides
Alternative Parents
Diphenylmethanes / C-glycosyl compounds / Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Chlorobenzenes / Aryl chlorides / Oxanes / Monosaccharides / Oxolanes
show 7 more
Substituents
Phenolic glycoside / Diphenylmethane / C-glycosyl compound / Phenoxy compound / Phenol ether / Alkyl aryl ether / Chlorobenzene / Halobenzene / Benzenoid / Monosaccharide
show 17 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
aromatic ether, monochlorobenzenes, C-glycosyl compound, tetrahydrofuryl ether (CHEBI:82720 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Inhibitor
General Function
Low-affinity glucose:sodium symporter activity
Specific Function
Sodium-dependent glucose transporter. Has a Na(+) to glucose coupling ratio of 1:1.Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capac...
Gene Name
SLC5A2
Uniprot ID
P31639
Uniprot Name
Sodium/glucose cotransporter 2
Molecular Weight
72895.995 Da
References
  1. Vivian EM: Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Drugs Context. 2014 Dec 19;3:212264. doi: 10.7573/dic.212264. eCollection 2014. [PubMed:25598831 ]

Drug created on March 31, 2015 20:20 / Updated on October 02, 2017 06:12